Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 840 results for "sanofi"

Sanofi (SNY) Showing Bearish Technicals With Resistance At $51.68

MarketIntelligenceCenter.com's patented trade-picking algorithms have identified an attractive covered-call trade on Sanofi-Aventis (http://www.marketintelligencecenter.com/symbol/SNY"SNY). Look at the Sep. '15 $50.00 covered call for a net debit in ... Individual.com, 18 hours ago
Sanofi-Aventis Shares Sinking Lower, Down 2.6% Individual.com, 2 days ago

73 images for sanofi

American Banking News - Forex, 2 days ago
Bio Spectrum Asia, 1 day ago
InvestorPoint.com, 23 hours ago
Pharma Letter, 1 day ago
Nutraceuticals World, 19 hours ago
Yahoo! Finance, 2 days ago
Saudi Gazette, 4 days ago
Drug Discovery and Development, 1 day ago
India Infoline, 6 hours ago
Canada NewsWire, 23 hours ago
Pharmafile

Sanofi Announces Men With Advanced Prostate Cancer in England Will Continue to Have Access to Cabazitaxel..

/PRNewswire/ -- − Sanofi works with NHS England on interim agreement until NICE re-appraisal − Sanofi announced today that it has reached agreement with NHS England that cabazitaxel will once more be available on the NHS to clinically ...
 ADVFN India22 hours ago Sanofi prostate cancer drug to remain on CDF  Pharmafile2 days ago Sanofi's Global Head for Prostate Drug, Zhen Su, Leaves Company  Bloomberg6 days ago
[x]  
EuroInvestor

German Chancellor, Sanofi Push for Addtl Antibiotics Research Initiatives

German chancellor Dr. Angela Merkel met with Sanofi CEO Dr. Olivier Brandicourt, Boris Rhein, Hesse's Minister for Science and the Arts, leaders of the Fraunhofer Society and researchers from Sanofi to discuss the current status of antibiotics ...
 PharmaAsia6 hours ago New decision regarding MT Højgaard Group's activities at Thule  EuroInvestor15 hours ago Sanofi hosts Angela Merkel at Frankfurt site  European Pharmaceutical Manufacturer19 hours ago Sanofi Hosts German Chancellor Angela Merkel at Frankfurt Site  EuroInvestor1 day ago
[x]  

Rosa & Co. Announces Multi-Year, World-Wide PhysioPD Research Agreement with Sanofi

SAN CARLOS, Calif. , May 28, 2015 /PRNewswire/ --Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced the initiation of a multi-year Research Agreement with Sanofi Global R&D to ...
 BioSpace23 hours ago Rosa Co. Announces Multi-Year, World-Wide PhysioPD Research Agreement with Sanofi  BioMedReports21 hours ago
[x]  
Xconomy

Sanofi buys priority review voucher for $245 million

Sanofi is spending $245 million to get hold of a voucher from the USA's Retrophin that can be used to speed up approval of a compound from its pipeline. Retrophin got hold of a Rare Pediatric Disease Priority Review Voucher when it bought ...
 Pharma Field1 day ago Retrophin bags $245M from Sanofi for priority review voucher  Seeking Alpha1 day ago ViewPoints: Sanofi coy on how newly acquired priority review voucher will be used  FirstWord Pharma1 day ago Sanofi to acquire FDA priority review voucher from Retrophin for $245 million  FirstWord Pharma1 day ago
[x]  
Pharma Letter

NeuroVive Asia teams up with Sanofi to develop & commercialization CicloMulsion in South Korea

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that NeuroVive Pharmaceutical Asia group has signed a collaboration agreement with Sanofi's local affiliate for the development and commercialization of CicloMulsion ...
 PharmaBiz1 day ago NeuroVive Asia, Sanofi to Jointly Develop and Market Ciclomulsion in South Korea  PharmaAsia1 day ago NeuroVive Asia signs deal with Sanofi for CicloMulsion in South Korea  Pharma Letter1 day ago NeuroVive Asia Inks Collaboration Deal With Sanofi For Growth Of CicloMulsion  RTTNews.com3 days ago
[x]  

Amgen, Inc. Or Sanofi SA (ADR) - Who Will Rule The Cholesterol Market?

Amgen, Inc. ( NYSE:AMGN ) and Sanofi SA ADR ( NYSE:SNY ) are all set to change the cholesterol drug market with their powerful new treatments that belong to a new class of drugs called PCSK9 protein inhibitors. The inhibitors work by targeting the ...
 Bidness Etc1 day ago Amgen vs. Sanofi: Cholesterol Blockbuster Battle  Converter News1 day ago Amgen's Cholesterol Fighting Drug Receives EU Approval  Guru Focus2 days ago
Canada NewsWire

The Sanofi Group in Canada Steps Up for Employee Health

Employees lace up their running shoes to boost their daily physical activity levels and compete in the Global Corporate Challenge LAVAL, QC, May 27, 2015 /CNW Telbec/ - The Sanofi group in Canada is excited to announce that it will enter 57 teams ...
 Bloomberg1 day ago
[x]  
Bio Spectrum Asia

Swedish firm partners with Sanofi to expand in Asia

Singapore: Sweden-based company NeuroVive Pharmaceutical's Asia arm has signed a collaboration agreement with Sanofi's affiliate for the development and commercialization of CicloMulsion in South Korea. Under the agreement NeuroVive Asia will get ...
 Bio Spectrum Asia2 days ago

NeuroVive and Sanofi to develop and commercialise Ciclomulsion in South Korea

NeuroVive Pharmaceutical Asia has entered a collaboration agreement with Sanofi's local subsidiary to develop and commercialise CicloMulsion in South Korea. NeuroVive's CicloMulsion, which is in a clinical development phase, is being developed to ...
 Pharmaceutical Technology3 days ago Sanofi to Co-Develop NeuroVive's CicloMulsion in South Korea  Genetic Engineering News2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - sanofi
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less